These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 34590328)

  • 1. Hydroxychloroquine for Primary Progressive Multiple Sclerosis.
    Koch MW; Kaur S; Sage K; Kim J; Levesque-Roy M; Cerchiaro G; Yong VW; Cutter GR; Metz LM
    Ann Neurol; 2021 Dec; 90(6):940-948. PubMed ID: 34590328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis.
    Camara-Lemarroy C; Silva C; Gohill J; Yong VW; Koch M
    Eur J Neurol; 2023 Jan; 30(1):187-194. PubMed ID: 36214614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repurposing Domperidone in Secondary Progressive Multiple Sclerosis: A Simon 2-Stage Phase 2 Futility Trial.
    Koch MW; Sage K; Kaur S; Kim J; Cerchiaro G; Yong VW; Cutter GR; Metz LM
    Neurology; 2021 May; 96(18):e2313-e2322. PubMed ID: 34038379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Hydroxychloroquine and Indapamide Attenuates Neurodegeneration in Models Relevant to Multiple Sclerosis.
    Brown D; Moezzi D; Dong Y; Koch M; Yong VW
    Neurotherapeutics; 2021 Jan; 18(1):387-400. PubMed ID: 33410109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial.
    Wolinsky JS; Montalban X; Hauser SL; Giovannoni G; Vermersch P; Bernasconi C; Deol-Bhullar G; Garren H; Chin P; Belachew S; Kappos L
    Ann Neurol; 2018 Oct; 84(4):527-536. PubMed ID: 30155979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial.
    Chataway J; De Angelis F; Connick P; Parker RA; Plantone D; Doshi A; John N; Stutters J; MacManus D; Prados Carrasco F; Barkhof F; Ourselin S; Braisher M; Ross M; Cranswick G; Pavitt SH; Giovannoni G; Gandini Wheeler-Kingshott CA; Hawkins C; Sharrack B; Bastow R; Weir CJ; Stallard N; Chandran S;
    Lancet Neurol; 2020 Mar; 19(3):214-225. PubMed ID: 31981516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine reduces microglial activity and attenuates experimental autoimmune encephalomyelitis.
    Koch MW; Zabad R; Giuliani F; Hader W; Lewkonia R; Metz L; Wee Yong V
    J Neurol Sci; 2015 Nov; 358(1-2):131-7. PubMed ID: 26344560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.
    Koch MW; Mostert J; Repovic P; Bowen JD; Comtois J; Strijbis E; Uitdehaag B; Cutter G
    J Neurol; 2022 Oct; 269(10):5319-5327. PubMed ID: 35570237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon Beta for primary progressive multiple sclerosis.
    Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006643. PubMed ID: 20091602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta for primary progressive multiple sclerosis.
    Rojas JI; Romano M; Ciapponi A; Patrucco L; Cristiano E
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006643. PubMed ID: 19160292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
    Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
    Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
    Wolinsky JS; Arnold DL; Brochet B; Hartung HP; Montalban X; Naismith RT; Manfrini M; Overell J; Koendgen H; Sauter A; Bennett I; Hubeaux S; Kappos L; Hauser SL
    Lancet Neurol; 2020 Dec; 19(12):998-1009. PubMed ID: 33129442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
    Goldberg SB; Supko JG; Neal JW; Muzikansky A; Digumarthy S; Fidias P; Temel JS; Heist RS; Shaw AT; McCarthy PO; Lynch TJ; Sharma S; Settleman JE; Sequist LV
    J Thorac Oncol; 2012 Oct; 7(10):1602-8. PubMed ID: 22878749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.